Silence Therapeutics PLC (SLN) Key Ratios

$11.18

up-down-arrow $-0.04 (-0.36%)

As on 25-Sep-2026 16:00EDT

Market cap

info icon

$695 Mln

Revenue (TTM)

info icon

$1 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

18.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -97.63 -72.21 -42.96
EBIT 12.20 57.77 26.29 -10.62 -15.56
Net Profit 17.69 67.24 31.30 -17.85 -11.02
EPS 17.70 67.24 31.24 -2.91 -191.54
Book Value -- -- -42.51 29.02 66.00
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -5,387.55-3,352.19-9,892.63-15,849.91-114.62
Net Margin info -----9,759.23----
Return on equity info -123.75-217.53-118.98-104.65-70.22
Return on Capital info -122.58-213.46---104.49-70.02
Return on Assets info -46.20-44.43-40.08-60.43-35.35
Debt to Equity (x) info ----0.000.000.00
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
-104.49
-70.02
-193.22
-263.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-118.98

Lower than Peers by 101.37

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-118.98
-104.65
-70.22
-196.38
-268.20
Peer Median
-17.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-40.08

Lower than Peers by 27.57

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-40.08
-60.43
-35.35
-42.83
-40.29
Peer Median
-12.52
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-9,892.63

Lower than Peers by 9,834.80

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-9,892.63
-15,849.91
-114.62
-198.13
-228.99
Peer Median
-57.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-9,759.23

Lower than Peers by 9,696.88

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-9,759.23
-15,851.88
-104.74
-170.51
-232.44
Peer Median
-62.35
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.02

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-0.02
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

-97.63

Lower than Peers by 120.52

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-97.63
-0.99
0.70
0.44
0.42
Peer Median
22.88
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

26.29

Higher than Peers by 12.09

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
26.29
-78.70
1.38
-24.37
11.83
Peer Median
14.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

31.30

Higher than Peers by 20.12

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
31.30
-95.57
-4.72
-5.45
-4.12
Peer Median
11.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

31.24

Higher than Peers by 2.30

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
31.24
-0.93
0.11
0.04
-1.58
Peer Median
28.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-59.14

Lower than Peers by 60.92

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-59.14
--
--
--
--
Peer Median
1.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
0.00
0.00
0.01
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
0.00
0.00
0.00
0.01
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

7.42

Higher than Peers by 2.78

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
7.42
8.72
11.14
4.62
4.41
Peer Median
4.64
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

7.42

Higher than Peers by 2.81

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
7.42
--
--
5.67
5.15
Peer Median
4.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
--
--
-1,478.71
-860.09
Peer Median
0.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

1,512.64

Higher than Peers by 1,487.02

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
1,512.64
4,403.22
1.79
74.78
5.18
Peer Median
25.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.00

Lower than Peers by 0.24

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
0.00
0.00
0.34
0.25
0.17
Peer Median
0.25
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
8,295.02
83.38
143.14
12.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
--
-575.40
-620.05
-273.35
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
6,253.37
86.63
103.29
120.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
--
-578.65
-580.20
-381.11
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
-1.08
-2.36
-5.30
-4.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

18.60

Higher than Peers by 15.01

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
18.60
1.54
1.00
10.43
8.28
Peer Median
3.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-5.78

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
-5.78
-0.12
0.22
-3.52
-2.80
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

695

Higher than Peers by 621

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Silence Therapeutics PLC (SLN)
695
--
--
--
--
Peer Median
74
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...